Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma—a “real world” studyNarendranath Epperla, Timothy S. Fenske, Eunhye Oak et al.|Hematological Oncology|2017Cited by 68
Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory (R/R) mantle cell lymphoma (MCL).Narendranath Epperla, Timothy S. Fenske, Mehdi Hamadani et al.|Journal of Clinical Oncology|2016Cited by 0